Molecular hydrogen in cancer therapy: Bioactive materials for tumor-targeted delivery and in situ generation
Journal of Controlled Release · 2026
DOI: 10.1016/j.jconrel.2026.115137 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Controlled Release, 2026. Verfasst von Jianfeng Wu und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Medicinal Chemical Biology, College of Life Science, Nankai University, Tianjin 300350, China; Nankai International Advanced …. Hauptthemen laut MEDLINE: Neoplasms, Hydrogen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 216 Literaturangaben. Gefördert von: Guangdong Basic and Applied Basic Research Foundation, Basic and Applied Basic Research Foundation of Guangdong Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Molecular hydrogen (H2) therapy has emerged as a promising adjunctive strategy in oncology, primarily attributed to its selective antioxidant, anti-inflammatory, and cytoprotective properties. Advances have been driven by the integration of mechanistic studies on H2-mediated redox regulation, immunoregulation, and cytoprotective effects with rapid developments in nanotechnology and catalysis. Nevertheless, the clinical translation of H2 therapy remains constrained by the present physicochemical limitations, including low solubility, non-targeted diffusion, the incomplete understanding of therapeutic mechanisms, etc. This review summarizes recent progress in molecular H2 research, spanning from fundamental mechanisms in cancer biology, the role in adjuvant therapy, to the development of innovative catalytic delivery systems, such as stimuli-responsive materials and hydrogenases. We outline the pertinent challenges and future directions, emphasizing the need for mechanistic elucidation and robust clinical validation to integrate hydrogen therapy into precision oncology paradigms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Medicinal Chemical Biology, College of Life Science, Nankai University, Tianjin 300350, China; Nankai International Advanced Research Institute (Shenzhen Futian), Shenzhen, Guangdong 518045, Chin…
Förderung
- Guangdong Basic and Applied Basic Research Foundation
- Basic and Applied Basic Research Foundation of Guangdong Province
- National Natural Science Foundation of China
Zitieren
APA
Wu, J., Lai, T. P., Li, L., Yuan, Y., Wang, Y., Liu, G., Li, W., Zhang, L., & Wan, L. (2026). Molecular hydrogen in cancer therapy: Bioactive materials for tumor-targeted delivery and in situ generation. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2026.115137
Vancouver
Wu J, Lai TP, Li L, Yuan Y, Wang Y, Liu G, et al. Molecular hydrogen in cancer therapy: Bioactive materials for tumor-targeted delivery and in situ generation. Journal of Controlled Release. 2026. doi:10.1016/j.jconrel.2026.115137
BibTeX
@article{Wu2026,
author = {Wu, Jianfeng and Lai, Tin Pou and Li, Liangyan and Yuan, Yong and Wang, Yaling and Liu, Guozheng and Li, Wangzhe and Zhang, Liyun and Wan, Lei},
title = {Molecular hydrogen in cancer therapy: Bioactive materials for tumor-targeted delivery and in situ generation},
journal = {Journal of Controlled Release},
year = {2026},
doi = {10.1016/j.jconrel.2026.115137}
}
EUVIMED